Zilico at Digital Medicine and Medtech Showcase 2019 Press Release

Thursday 3rd January 2019

Zilico to announce plans for the future development of its EIS technology in cancer diagnostics

Zilico Limited’s CEO, Sameer Kothari, will be presenting at the annual Digital Medicine and Medtech Showcase, to announce how Zilico will be further developing its portfolio of cancer diagnostic devices based on its patented Electrical Impedance Spectroscopy (EIS) technology. The presentation will be on the 9th January 2019 at 10.45 at the Parc 55 San Francisco - a Hilton Hotel, in the Powell-II (level 3).

Zilico's patented EIS technology is scientifically-proven, provides a real-time objective assessment to differentiate between normal, pre-cancerous and cancerous tissues. Zilico are developing the next generation of diagnostic devices using EIS to minimise subjectivity and increase diagnostic accuracy across a range of neoplastic conditions, including cervical, oral, oesophageal and anal cancers. Initial data from intraoperative device usage demonstrates that EIS also enables surgical robotics to address tissue margin recognition, which is a significant market need in cancer surgery.

2018 saw Zilico continue global expansion and growth with two investments totalling $19million for their lead product, ZedScan™.  As part of this growth Zilico secured a strategic deal with the MaxHealth Medicine Group (China), stock code: 836163 (NEEQ) which permits MaxHealth to sell and market ZedScan™, Zilico’s cervical cancer diagnostic system, to the Chinese market. The deal will see Zilico receive minimum royalties of $12million.

In addition to the Chinese deal, Zilico has also announced investments totalling $7M from Deepbridge Capital (UK). Both investments continue to help Zilico further drive the adoption of ZedScan™ across the UK and Europe as well as taking the product through its regulatory trials in the US. The company has appointed Dr Michael Gold, Past President of the ASCCP and Dr Warner Huh, Associate Professor of Gynecologic Oncology, University of Alabama and Birmingham, to its Medical Advisory Board in preparation for entering the US market.

During the Digital Medicine and Medtech Showcase, CEO, Sameer Kothari will be available for one-to-one meetings. To book one of these meetings you can login using your event details https://ebdgroup.knect365.com/biotech-showcase/partnering, call +44 (0)161 826 7840 or email your availability to info@zilico.co.uk.

 (ENDS)

For media enquiries please contact:

Rebecca Lovell, Onyx Health                                     

Tel: +44 (0) 191 640 3638                                          

E-mail: rlovell@onyxhealth.com                                 

Zilico Ltd

Zilico's product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) technology, applicable to a wide range of neoplastic conditions. The company prides itself on creating innovative technology that removes subjectivity, increases accuracy and delivers results in real-time. Zilico's head office is located in Manchester, UK. Manufacturing and R&D functions are also carried out in the UK and Zilico achieved ISO 13485 accreditation in 2013.

MaxHealth Medicine Group

Established in 2009, the MaxHealth Medicine Group works with world-class manufacturers of pharmaceutical products and medical technologies to open up the Chinese market to them.  MaxHealth has an interest in medical technologies that can transform existing treatment processes and bring about significant benefits to patient and physicians. The company partners with innovative companies to commercialise medical technologies for the Chinese market through investments, joint ventures and technology licensing.

News